Longitudinal study of immune response and epigenetics in acute LongCovid syndrome secondary to COVID-19 disease.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027314

Enrollment

100

Registered

2023-01-02

Start date

2022-09-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-COVID-19 syndrome U09.9

Interventions

Group 1: Repeated blood tests in patients with LongCovid syndrome over a period of 1 year each.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Good physical condition (Karnofsky index =80%). Previous laboratory diagnostic evidence of SARS-CoV-2 infection. Current existing LongCovid syndrome.

Exclusion criteria

Exclusion criteria: Hemoglobin <10 g/dL Symptomatic heart disease (e.g., heart failure NYHA =II, coronary artery disease) previous myocardial infarction COPD Stage GOLD III-IV Body weight less than 45kg <8 weeks (men) or <12 weeks (women) since last blood collection of =500 ml

Design outcomes

Primary

Measure	Time frame
Identification of characteristic blood markers in LongCovid syndrome.	—

Countries

Germany

Contacts

Public ContactClara Lehmann

Klinische Infektiologie, Klinik I für Innere MedizinUniversitätsklinikum Köln (AöR)

clara.lehmann@uk-koeln.de+49 221 478 38374

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026